Journal
VACCINE
Volume 25, Issue 13, Pages 2518-2527Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2006.09.029
Keywords
pneumococcal conjugate vaccine; opsonophagocytic antibodies; assay validation
Categories
Ask authors/readers for more resources
Immunological evaluation of the clinical impact of vaccines designed to protect against infection by Streptococcus pneumoniae requires measurement of serotype-specific functional antibodies. We describe the development and validation of a viable pneumococcal opsonophagocytosis assay (OPA) that can be used for routine serological analysis of paediatric immune responses after immunization. OPA seropositivity (% >= 8 threshold) reflected well invasive pneumococcal disease (IPD) effectiveness. In contrast, the 22F inhibition ELISA seropositivity (% >= 0.20 mu g/ml threshold) overestimated (19F) or underestimated (6B, 23F, 6A) IPD effectiveness for several serotypes. The seropositivity as estimated by a standardized and highly reproducible OPA was predictive for the serotype-specific IPD efficacy of pneumococcal conjugate vaccines. (C) 2006 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available